Follow the people · Insider
Russell Skibsted
Russell Skibsted files insider transactions with the SEC as a chief financial officer of Processa Pharmaceuticals (PCSA). We hold 7 disclosed purchases and sales filed since 19 May 2011, 2 of them in the last 90 days.
- Files forPCSA
- Disclosed buys and sells7 in all, 2 in the last 90 days
- Last disclosure1 July 2026
Positions held
5 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 16 July 2024 — 26 July 2026Chief Financial Officer · Processa Pharmaceuticals (PCSA)12 Form 4 lines · source: SEC Form 4
- Filed 9 January 2023 — 21 November 2023Chief Financial Officer & SVP · Alimera Sciences (ALIM)4 Form 4 lines · source: SEC Form 4
- Filed 15 September 2020 — 9 September 2022Officer · Rockwell Medical (RMTI)3 Form 4 lines · source: SEC Form 4
- Filed 8 September 2016 — 18 December 2018Chief Financial Officer · Biotime (BTX)10 Form 4 lines · source: SEC Form 4
- Filed 18 May 2011 — 8 March 2013Chief Financial Officer · Aeolus Pharmaceuticals (AOLS)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
34 entries, newest first — one per disclosure report, one per Form 4 line- was granted 11,883 shares of Processa Pharmaceuticals (a derivative holding)SEC Form 428 July 2026Restricted Stock Units · traded 26 July 2026 · filed 28 July 2026
- ▲ bought on the open market 3,277 shares of Processa PharmaceuticalsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- ▲ bought on the open market 2,654 shares of Processa PharmaceuticalsSEC Form 416 June 2026Common Stock · traded 15 June 2026 · filed 16 June 2026
- ▲ bought on the open market 2,292 shares of Processa PharmaceuticalsSEC Form 41 June 2026Common Stock · traded 29 May 2026 · filed 1 June 2026
- ▲ bought on the open market 1,984 shares of Processa PharmaceuticalsSEC Form 419 May 2026Common Stock · traded 15 May 2026 · filed 19 May 2026
- ▲ bought on the open market 2,190 shares of Processa PharmaceuticalsSEC Form 41 May 2026Common Stock · traded 30 April 2026 · filed 1 May 2026
- ▲ bought on the open market 1,984 shares of Processa PharmaceuticalsSEC Form 417 April 2026Common Stock · traded 15 April 2026 · filed 17 April 2026
- ▲ bought on the open market 2,324 shares of Processa PharmaceuticalsSEC Form 41 April 2026Common Stock · traded 31 March 2026 · filed 1 April 2026
- was granted 108,000 shares of Processa Pharmaceuticals (a derivative holding)SEC Form 43 October 2025Restricted Stock Units · traded 1 October 2025 · filed 3 October 2025
- was granted 324,000 shares of Processa Pharmaceuticals (a derivative holding)SEC Form 43 October 2025Stock Options (Right to Buy) · traded 1 October 2025 · filed 3 October 2025
- was granted 1,775,044 shares of Processa Pharmaceuticals (a derivative holding)SEC Form 428 July 2025Restricted Stock Units · traded 24 July 2025 · filed 28 July 2025
- was granted 28,000 shares of Processa Pharmaceuticals (a derivative holding)SEC Form 418 July 2024Restricted Stock Units · traded 16 July 2024 · filed 18 July 2024
- was granted 50,000 shares of Alimera Sciences (a derivative holding)SEC Form 428 November 2023Employee Stock Option (Right to Buy) · traded 21 November 2023 · filed 28 November 2023
- was granted 58,000 shares of Alimera SciencesSEC Form 428 March 2023Common Stock · traded 26 March 2023 · filed 28 March 2023
- was granted 52,500 shares of Alimera Sciences (a derivative holding)SEC Form 410 January 2023Employee Stock Option (Right to Buy) · traded 9 January 2023 · filed 10 January 2023
- was granted 17,500 shares of Alimera SciencesSEC Form 410 January 2023Common Stock · traded 9 January 2023 · filed 10 January 2023
- was granted 80,000 shares of Rockwell Medical (a derivative holding)SEC Form 413 September 2022Stock Option (Right to Buy) · traded 9 September 2022 · filed 13 September 2022
- was granted 600,000 shares of Rockwell Medical (a derivative holding)SEC Form 416 September 2020Stock Option (Right to Buy) · traded 15 September 2020 · filed 16 September 2020
- was granted 150,000 shares of Rockwell Medical (a derivative holding)SEC Form 416 September 2020Stock Option (Right to Buy) · traded 15 September 2020 · filed 16 September 2020
- exercised options over 22,500 shares of Biotime (a derivative holding)SEC Form 420 December 2018Restricted Stock Units · traded 18 December 2018 · filed 20 December 2018
- exercised options over 22,500 shares of BiotimeSEC Form 420 December 2018Common Shares, no par value · traded 18 December 2018 · filed 20 December 2018
- had shares withheld for tax on 7,781 shares of BiotimeSEC Form 420 December 2018Common Shares, no par value · traded 18 December 2018 · filed 20 December 2018
- exercised options over 11,250 shares of BiotimeSEC Form 49 October 2018Common Shares, no par value · traded 4 October 2018 · filed 9 October 2018
- had shares withheld for tax on 3,891 shares of BiotimeSEC Form 49 October 2018Common Shares, no par value · traded 4 October 2018 · filed 9 October 2018
- exercised options over 11,250 shares of Biotime (a derivative holding)SEC Form 49 October 2018Restricted Stock Units · traded 4 October 2018 · filed 9 October 2018
- was granted 150,000 shares of Biotime (a derivative holding)SEC Form 419 March 2018Option to Purchase Common Shares · traded 15 March 2018 · filed 19 March 2018
- ▲ bought on the open market 2,000 shares of BiotimeSEC Form 425 August 2017Common Shares, no par value · traded 23 August 2017 · filed 25 August 2017
- was granted 250,000 shares of Biotime (a derivative holding)SEC Form 48 June 2017Option to Purchase Common Shares · traded 6 June 2017 · filed 8 June 2017
- was granted 50,000 shares of Biotime (a derivative holding)SEC Form 49 September 2016Option to Purchase Common Shares · traded 8 September 2016 · filed 9 September 2016
- was granted 150,000 shares of Aeolus Pharmaceuticals (a derivative holding)SEC Form 411 March 2013Non-qualified Stock Option (right to buy) · traded 8 March 2013 · filed 11 March 2013
- ▲ bought on the open market 7,027 shares of Aeolus PharmaceuticalsSEC Form 423 May 2012Common Stock · traded 23 May 2012 · filed 23 May 2012
- ▲ bought on the open market 5,000 shares of Aeolus PharmaceuticalsSEC Form 419 May 2011Common Stock · traded 18 May 2011 · filed 19 May 2011
- ▲ bought on the open market 5,000 shares of Aeolus PharmaceuticalsSEC Form 419 May 2011Common Stock · traded 18 May 2011 · filed 19 May 2011
- ▲ bought on the open market 10,000 shares of Aeolus PharmaceuticalsSEC Form 419 May 2011Common Stock · traded 18 May 2011 · filed 19 May 2011
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.